Cambrex Featured in Manufacturing Today Article
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, "Cambrex") was featured in the Summer 2010 edition of Manufacturing Today magazine. The article, Good Chemistry: Behind-the-Scenes Advances in Technology at Cambrex Help Reduce the Risk for Manufacturers, provides an in-depth overview of Cambrex’s history, manufacturing capabilities, locations and recent acquisitions.
The article discusses how, even in the highly-regulated pharmaceutical marketplace, Cambrex’s manufacturing technologies, quality and process systems successfully operate in compliance with laws and policies enforced not only by regulatory agencies including the Food and Drug Administration (“FDA”) and the Drug Enforcement Administration (“DEA”), but also by customers.
High Potency Active Pharmaceutical Ingredient (“HPAPI”) development and manufacturing, drug delivery and biocatalysis were cited as examples of how Cambrex has acquired highly specialized capabilities to differentiate itself from competitors. These capabilities place Cambrex at the forefront of API manufacturing technology and offer customers technologies that can result in cost and quality advantages for their projects. In addition, Cambrex’s novel Continuous-Flow Microwave-Assisted Organic Synthesis (“CF-MAOS”) technology was highlighted for its innovative, scalable and efficient capabilities in using microwave technology in a continuous manufacturing arrangement that results in yield, quality and cost improvements to processes for manufacturing APIs.
According to its website, the digital and print magazine supplies its 36,000 readers with case studies and strategies with best practices from all realms of the manufacturing industry.
Cambrex’s article in Manufacturing Today can be viewed online.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.